EVLV Stock Analysis: Q1 Growth, Higher Bar

EVLV stock analysis is more interesting after Q1 than it was before earnings, but only if you respect the risk. Evolv just posted $46.3 million in first-quarter revenue, up 45% year over year, raised full-year guidance to $175 million to $180 million, and kept adjusted EBITDA positive at $3.9 million. The stock was trading around $6.51 on June 3, which still leaves room if the company executes. It is not a cheap no-brainer, though. This is still a company with a GAAP loss, debt covenants, and a history that makes people hesitate.

The setup is simple: Evolv is proving there is real demand for faster weapons screening, and the market still is not fully sure how durable that demand is. If you buy that recurring revenue keeps compounding and the June 9 investor day reinforces the story, the stock can work. If you think this is another flashy hardware-adjacent small cap that stalls out before real profitability, you can make a fair bear case too.

What changed since our last EVLV stock analysis

Our last EVLV piece was written before the May 12 earnings report. That matters, because this quarter gave us the first clean read on whether the business was still accelerating after the strong 2025 finish.

What we got was good. Total revenue came in at $46.3 million, up from $32.0 million a year earlier. ARR ended the quarter at $127.3 million, up 20% year over year. Adjusted EBITDA was $3.9 million, versus $2.1 million last year. Management also raised its 2026 revenue guide to $175 million to $180 million and said year-end ARR should land between $145 million and $150 million.

There was a weird side note too: on May 13, Evolv filed an 8-K because some market-data sites had misreported the quarter. That does not change the fundamentals, but it does tell you the stock is still underfollowed enough that bad summary data can circulate for a full day. In small caps, that kind of confusion can create both opportunity and volatility.

The newer operating updates also help. Evolv announced a June 9 investor day, which gives management a near-term stage to tighten the story around growth, products, and margin progression. It also published new customer evidence from Bank of America Stadium, where the company said the venue renewed and upgraded its deployment and achieved a 93% clear rate at fan entrances. For a business selling speed and throughput, that is the kind of proof point investors want.

The numbers that actually matter

The headline growth is real, but the mix matters more than the headline. Recurring revenue was $31.2 million in Q1, up 21% year over year. Non-recurring revenue was $15.2 million, up 142%. That second number is great for the quarter, but it is also the lumpier part of the model. The long game is still about getting more customers onto subscriptions and keeping them there.

Gross profit was $23.6 million, up from $19.2 million a year ago. Operating expenses fell slightly year over year to $32.1 million from $33.5 million, which is a good sign because it shows some discipline even while the company is still hiring in go-to-market roles. General and administrative expense dropped 10%, helped by lower non-recurring professional fees tied to the old investigation and restatement mess.

The balance sheet is decent, not pristine. Evolv ended March with $61.1 million in cash, cash equivalents, and marketable securities. It also had $30.0 million drawn on its MidCap credit facility, with another $45.0 million available between the delayed-draw term loan and revolver. That gives the company room, but this is not a zero-debt story anymore.

At roughly a $1.17 billion market cap on June 3, EVLV trades at about 6.6x the midpoint of 2026 revenue guidance. TTM revenue sits around $160.2 million. Net income is still negative, so there is no real P/E to lean on yet. That is important. You are not buying a cheap earnings multiple here. You are paying a growth multiple for a company that is getting closer to durable profitability, but is not there yet.

That is a very different setup from something like ICHR, where the debate is more about cyclical semiconductor demand and less about proving the business model. EVLV still has to earn investor trust quarter by quarter.

Why the bull case still works

The cleanest bull argument is that Evolv is selling a real operational improvement, not a science project. Schools, stadiums, hospitals, and entertainment venues do not want old-school metal detector lines if they can avoid them. If Evolv can keep showing that people move through quickly while venues still catch threat items, adoption can keep spreading without the company needing some magical TAM story to justify it.

The installed-base story still looks healthy. Management said growth came from both new customer acquisition and expansion inside the existing base. That matters because expansion revenue is usually better revenue. It suggests customers are not just trying the system and walking away. They are adding units, upgrading deployments, and using newer products like eXpedite.

There is also a path to a better quality revenue mix. Subscription revenue was $23.1 million in Q1 and service revenue was $8.6 million. Product revenue jumped to $13.4 million from just $2.3 million a year ago, which juiced the quarter, but the recurring side still anchors the thesis. If management can keep ARR growth around 20% while lifting margins, this stops being viewed as a novelty security stock and starts getting treated more like a recurring-revenue industrial tech name.

I also like that the business is no longer living off vague momentum language. The company now has concrete operating proof points. It says its systems have screened more than 4 billion people since 2019. Bank of America Stadium renewed and upgraded. Investor day is next week. Those are not final answers, but they are better than buzzword slides.

The market may also still be underpricing the possibility that 2026 is the year EVLV graduates from “interesting SPAC leftover” to “real small-cap compounder.” That sounds aggressive, but the ingredients are there: 45% Q1 growth, positive adjusted EBITDA, raised guidance, and enough liquidity to keep investing.

The bear case is not hard to make

The obvious problem is that GAAP profitability still is not here. EVLV lost $5.0 million in Q1, worse than the $1.7 million loss a year ago. Some of that noise comes from fair-value adjustments and financing costs, but the basic point stands: this business is improving, not finished.

The second problem is balance-sheet quality. Cash of $61.1 million is fine. Debt of $30.0 million is manageable. But the company is operating under credit covenants tied to ARR and liquidity, with an EBITDA covenant set to kick in later. Management says it expects to stay compliant. That is good. It is still a reminder that this story has less margin for error than a cash-rich software name.

The third issue is legal and cleanup risk. Evolv disclosed a $15.0 million settlement accrual tied to class-action litigation, offset by a $14.3 million estimated insurance recovery. That is not a thesis killer, but it is exactly the kind of scar tissue that makes institutions slow to fully trust a story again. We have written before about why that matters in our small-cap promotion trap checklist. EVLV is better than the obvious promotion traps, but it still carries some of the same market baggage.

The fourth issue is valuation. A 6.6x forward revenue multiple is not crazy if growth holds above 20% and margins keep improving. It is also not cheap if growth slips into the mid-teens or if customers start delaying deployments. This is why I would not put EVLV in the same bucket as deep-value small caps. It is a growth story. Growth stories get punished fast when the slope changes.

The fifth issue is execution risk on the newest products. eXpedite looks promising, but new product enthusiasm is easy. Scaled adoption is harder. We made a similar point in our HYLN stock analysis: a real catalyst does not erase the need for repeatable execution.

Valuation, price target, and my take

At around $6.51, EVLV is not screaming cheap, but it still looks mispriced enough to care about. Using the midpoint of 2026 guidance, the stock trades at about 6.6x sales. If Evolv earns a 7.5x to 8.5x multiple on roughly $177.5 million of revenue and keeps net cash positive, I get to a fair-value range of roughly $7.50 to $8.50 per share.

That is not moonshot math. It is also enough upside to matter in a small-cap portfolio if management keeps executing. The stock does not need perfection to work from here. It needs another couple of quarters showing ARR growth near 20%, positive adjusted EBITDA, and no fresh self-inflicted wounds.

The near-term swing factor is June 9 investor day. If management gives investors a cleaner long-range framework around margin progression, customer retention, and product mix, the market could start paying a better multiple. If the event turns into another glossy “AI security is the future” presentation with weak hard targets, the stock probably stays stuck.

Verdict: EVLV is compelling below $6.75, interesting up to about $7.50, and much less attractive above $8.50 unless the company proves there is another gear to growth. I would rather own it here than chase it after a hype spike. The business is getting better. The stock still needs proof.

Bottom line

This EVLV stock analysis comes down to one idea: the quarter was good enough to keep the thesis alive, but not clean enough to remove the discount. Revenue growth is strong. ARR is still compounding. Guidance moved up. Customer proof points are improving. The market cap is not absurd relative to that setup.

But this is still a story with real friction: a GAAP loss, debt, legal baggage, and a valuation that assumes management will keep stacking clean quarters. That is why I like EVLV as a selective small-cap growth bet, not as a blind “AI security” trade.

If investor day goes well and Q2 keeps the same shape, I think the stock can work into the high-$7s or low-$8s. If growth cools or execution gets messy again, the market will cut this multiple fast. That is the trade.

Sources

This article is for informational purposes only and does not constitute financial advice. Always do your own research and consider consulting with a financial advisor before making investment decisions.

marginofalpha.com currently holds a paper-portfolio position in EVLV.